Neurocrine Biosciences' (NBIX) Ingrezza, or valbenazine, capsules delivered improvements in uncontrolled movements and functional status in patients with tardive dyskinesia based on new data from a clinician survey, the company said late Monday.

Tardive dyskinesia is a neurological condition that involves involuntary movements.

In a subgroup analysis, nearly all people with the condition treated with the drug experienced fewer uncontrolled movements, and most showed an improvement in symptoms within four weeks, the company said.

Additionally, patients treated with the drug demonstrated "widespread improvements in functional status, independence, ability to perform daily activities and ability to work," Neurocrine said.

The results are being presented at the American Psychiatric Association annual meeting, which is taking place from May 16 to May 20 in San Francisco, the company said.